New pill targets Hard-to-Treat cancers with KRAS mutations
Disease control
Not yet recruiting
This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC